Mosaic Laboratories has been acquired by Caprion HistoGeneX
The shareholders of Mosaic Laboratories have sold the company to Caprion HistoGeneX.
Founded in 2005 by Lisa Dauffenbach and Chris Kerfoot, Mosaic Laboratories is a Lake Forest, California-based leading provider of bio-analytical testing services supporting translational, preclinical and clinical trial studies for a marquee roster of biotech and pharmaceutical clients globally. Mosaic pioneered proprietary multiplex immunohistochemistry (IHC) services that provide a superior ability to evaluate multiple biomarkers in a single tissue section, and has built a reputation among pharmaceutical companies to produce the most vivid IHC biomarker images. Mosaic supports the most rigorous clinical trial programs in the world, thereby impacting the future of patient therapies for cancer and other diseases.
Caprion HistoGeneX is a provider of proteomics and immune monitoring services for the pharmaceutical and biotechnology industry. The company operates two proprietary immune monitoring platforms that offer multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses while its proteomics business unit, as well as gel-free, label-free mass spectrometry (MS), provide comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers.
Oaklins’ team in Los Angeles acted as advisor to the seller in this transaction.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Related deals
Valmiermuižas Alus has been acquired by Cēsu Alus
Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreArmira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn more